Melanoma Trial, Recruiting NCT06418204 Sponsor: Wake Forest University Health Sciences Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT06418204
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older and have been recently diagnosed with breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer.
  • You are scheduled to receive chemotherapy (one or more drugs, including targeted therapy) and/or a type of immunotherapy called an immune checkpoint inhibitor — you can still join up until the start of your second round of treatment if you couldn't sign up before treatment began.
  • You are able to read and understand English or Spanish, as surveys are in these languages.
  • You have a working email address and are willing to fill out surveys online, whether at home, in the clinic, or elsewhere.
  • You have completed a confidential self-reported screening survey and received a result showing you are eligible.
  • You currently live in the United States, as confirmed by your own report on the screening survey.
  • Your doctor believes you have a life expectancy of at least 6 months.

Optional sub-study (only available at certain locations):

  • You are willing to take part in both the main study and an additional sub-study at Wake Forest University Comprehensive Cancer Center or Virginia Commonwealth University.
  • You are receiving your cancer treatment at one of those two specific locations.
  • You have been diagnosed with non-small cell lung cancer.
  • Your treatment plan includes a chemotherapy drug called paclitaxel along with an immune checkpoint inhibitor.

Who may not be able to join:

  • You are currently enrolled in another clinical trial focused on managing cancer symptoms.
  • You are currently pregnant.
  • You have previously received systemic cancer treatment for a prior cancer, including chemotherapy, immunotherapy, targeted therapy, or hormonal therapy.
  • You are currently enrolled in hospice care.

For the optional sub-study only:

  • You are regularly taking steroid medications or immune-modifying drugs (such as prednisone, dexamethasone, etanercept, or infliximab) — note that steroids taken as a pre-medication before chemotherapy are allowed (confirm with trial site).
  • You have a history of HIV, hepatitis B, or hepatitis C.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Glenn Lesser, MD, Wake Forest University Health Sciences

Phone: 336-716-0891

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 January 2025
Est. completion
1 August 2028

Where this trial is recruiting

Puerto Rico 🇺🇸 United States

Primary endpoints

Cancer-related symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov